Table 1.
Variable | Patient n (%) |
---|---|
Age at diagnosis | |
20–39 | 196 (24.1) |
40–49 | 258 (31.7) |
50–64 | 255 (31.4) |
65 ve üzeri | 104 (12.8) |
Menopausal status | |
Premenapausal | 471 (57.9) |
Postmenapausal | 342 (42.1) |
Histopathology | |
Invasive ductal | 729 (89.6) |
Invasive lobular | 40 (4.9) |
Mucinous | 12 (1.5) |
Mixed type | 12 (1.5) |
Other | 20 (2.5) |
Histologic Grade | |
I | 43 (5.3) |
II | 349 (42.9) |
III | 360 (44.3) |
Unknown | 61 (7.5) |
Disease stage | |
I | 32 (3.9) |
II | 350 (43.1) |
III | 362 (44.5) |
IV | 69 (8.5) |
ER status | |
ER+ | 577 (71) |
ER− | 227 (27.9) |
Unknown | 9 (1.1) |
PR status | |
PR+ | 580 (71.3) |
PR− | 221 (27.2) |
Unknown | 12 (1.5) |
HER2 status | |
HER2+ | 259 (31.9) |
HER2− | 544 (66.9) |
Unknown | 10 (1.2) |
Education level | |
None | 388 (47.7) |
Primary school | 268 (33) |
Junior-high school | 48 (5.9) |
High school | 63 (7.7) |
University | 46 (5.7) |
Residence | |
Urban | 655 (80.6) |
Rural | 158 (19.4) |
Economya | |
<500 TL | 186 (22.9) |
500–1500 TL | 309 (38) |
>1500 TL | 318 (39.1) |
Treatment type | |
Surgery | 731 (89.7) |
Chemotherapy | 695 (85.4) |
Radiotherapy | 535 (65.8) |
Hormonotherapy | 516 (63.4) |
Monthly family income level
ER: Estrogene receptor, PR: Progesteron receptor
HER2: Human epidermal growth factor receptor-2
n: Patient number